Treatment with the PARP inhibitor olaparib improves the outcomes of men with metastatic castration-resistant prostate cancer harboring deleterious mutations in homologous recombination repair genes, show trial results.
Adding apalutamide to androgen deprivation therapy does not result in increased levels of pain or fatigue, relative to placebo, nor does it negatively impact overall health-related quality of life, shows an analysis of data from the TITAN study.
Ultra-hypofractionated stereotactic body radiotherapy does not increase the risk for acute toxicity over standard of care radiotherapy in men with localized prostate cancer, according to a phase III trial.
Cabazitaxel could be an option for men with metastatic castration-resistant prostate cancer who have progressed after treatment with docetaxel and an androgen signaling-targeted agent, suggest trial findings.
An interim analysis from the SPARTAN trial points to an overall survival benefit with the use of apalutamide alongside androgen deprivation therapy for nonmetastatic castration-resistant prostate cancer.
Men with metastatic hormone-naïve prostate cancer have improved outcomes with the addition of docetaxel to androgen deprivation therapy irrespective of whether they have high or low burden of disease, indicates an analysis of the STAMPEDE trial.